Trial Profile
Public-interest Multicenter Umbrella Trial Based on Genetic Analysis in Korean Head and Neck Cancer and Esophageal Cancer Patient - Part 1 (HNSCC)]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Alpelisib (Primary) ; Durvalumab (Primary) ; Nintedanib (Primary) ; Poziotinib (Primary) ; Tremelimumab (Primary)
- Indications Head and neck cancer; Oesophageal cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- Acronyms KCSG HN 15-16 TRIUMPH Trial; TRIUMPH
- 12 Sep 2023 Results reporting safety and efficacy data over 12 months published in the Journal of Clinical Oncology
- 27 Mar 2022 Status changed from recruiting to completed.
- 05 Jun 2018 Results (n=93) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.